108796-58-3

Upstream product

• 501-53-1 benzyl chloroformate 
• 102312-67-4 cis-cyclohex-3-enyl-1,2-diamine dihydrochloride 
• 102312-67-4 rac-(trans)-cyclohex-4-ene-1,2-diamine dihydrochloride 
• 79-55-0 1,2,2,6,6-pentamethylpiperidine 
• 60-29-7 diethyl ether 

Downstream Products

• 108866-54-2 bis(phenylmethyl) (1α,2α,4α,5α)-(4,5-dihydroxy-1,2-cyclohexanediyl)bis(carbamate) 
• 108866-53-1 bis(phenylmethyl) (1α,2α,4β,5β)-(4,5-dihydroxy-1,2-cyclohexanediyl)bis(carbamate) 
• 108796-60-7 ((3R,4S)-4-Benzyloxycarbonylamino-7-oxa-bicyclo[4.1.0]hept-3-yl)-carbamic acid benzyl ester 
• 108866-47-3 cis-1,2-diamino-cis-4,5-dihydroxycyclohexane 
• 108866-48-4 cis-1,2-diamino-cis-4,5-dihydroxycyclohexane 
• 108866-62-2 Bis(phenylmethyl) (1α, 2α, 4α, 5α)-(4,5-diacetyloxy-1,2-cyclohexanediyl)bis(carbamate) 
• 108796-59-4 bis(phenylmethyl) (1α,2β,4α,5α)-(4,5-dihydroxy-1,2-cyclohexanediyl)bis(carbamate) 
• 108796-60-7 bis(phenylmethyl) (1α,3α,4β,6α)-7-oxabicyclo<4.1.0>heptane-3,4-diylbis(carbamate) 
• 108796-63-0 bis(phenylmethyl) (1α,2β,4α,5α)-(4,5-bis(acetyloxy)-1,2-cyclohexanediyl)bis(carbamate) 
• 108796-63-0 bis(phenylmethyl) (1α,2β,4β,5α)-(4,5-bis(acetyloxy)-1,2-cyclohexanediyl)bis(carbamate) 
• 108796-62-9 bis(phenylmethyl) (1α,2β,4α,5α)-(4-(acetyloxy)-5-hydroxy-1,2-cyclohexanediyl)bis(carbamate) 
• 108796-62-9 Acetic acid (1S,2S,4R,5R)-4,5-bis-benzyloxycarbonylamino-2-hydroxy-cyclohexyl ester 
• 105415-84-7 (1R,2S,4S,5S)-4,5-Diamino-cyclohexane-1,2-diol 
• 105415-84-7 (1R,2R,4R,5R)-4,5-Diamino-cyclohexane-1,2-diol 

Relevant academic research and scientific papers

DIAMINE DERIVATIVES

A compound represented by formula (1):Q1-Q2-To-N(R1) -Q3-N(R2)-T1-Q4 [wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 represents the following group: (wherein Q5 is an alkylene group having 1 to 8 carbon atoms, or the like); and T0 and T1 are carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

ETHYLENEDIAMINE DERIVATIVES

The invention relates a compound represented by the formula (1):Q1-Q2-C(=O)-N(R1)-Q3-N(R2)-T1-Q4 wherein R1 and R2 represent H or the like; Q1 represents an aromatic ring, heterocyclic ring or the like; Q2 represents a single bond, aromatic ring, heterocyclic ring or the like; Q3 represents a group or the like, Q4 represents an aromatic ring, heterocyclic ring or the like; and T1 represents -CO- or -SO2-, and a medicine which comprises the compound and is useful for thrombosis and embolism.

Noncovalent secondary interactions in Co(II)salen complexes: O2 binding and catalytic activity in cyclohexene oxygenation

The O2 affinity of Co(II)Salen complexes 1-4 and their reactivity in cyclohexene oxygenation reactions of Co(II)Salen complexes 1-4 are modulated by noncovalent interactions such as hydrogen bonding and steric hindrance using a functionalized diamino bridge. Higher O2 affinity is observed in the case of efficient hydrogen-bonding interactions (complex 1), while increased steric hindrance (cis vs trans diamino bridge) around the Co-coordinated O2 is influencing the reactivity of the complexes.

Diastereomeric mono- and di-substituted diamino cyclohexane compounds and the method of preparation thereof

One aspect of the present invention relates to a process of making cyclohexane-1,2-di(O)-4,5-di(N) diastereomers which are useful as a synthons for various diastereoisomeric pharmaceutical systems. The present invention also relates to the stereoisomer compounds which are derived from retro-synthetic analysis. In another aspect, the present invention relates to novel antineoplastic Pt(II) complexes derived from the stereoisomers and the processes for making such Pt(II) complexes. Mono- and di-hydroxyl substitution on the cyclohexane ring renders the organoplatinum complex relatively more water soluble, thereby facilitating intravenous administration. The Pt(II) complexes of the present invention are less nephrotoxic than cisplatin and are readily excreted via the kidney due to their enhanced water solubility. In a composition aspect, the present invention encompasses novel pharmaceutical compositions comprising the novel Pt(II) complexes in an amount sufficient to have an antineoplastic effect in an animal or patient.

Stereocontrolled Syntheses for the Six Diastereomeric 1,2-Dihydroxy-4,5-diaminocyclohexanes: PtII Complexes and P-388 Antitumor Properties

Stereocontrolled syntheses for the six diastereomeric 1,2-dihydroxy-4,5-diaminocyclohexanes 3a-f from cyclohexene diamines cis-4 and trans-5 are described.Cbz-protected species cis-9 and trans-11, respectively, served as a source of stable Cbz-protected p